A note on improved statistical approaches to account for pseudoprogression
- 126 Downloads
Responses to immuno-oncology agents are often subject to misinterpretation as apparent tumor growth due to immune infiltration leads to the appearance of progressive disease and can result in the discontinuation of effective therapeutic agents. Better statistical strategies to determine experimental outcomes are needed to distinguish between true and pseudoprogression. We applied time-to-event statistical analyses methods that account for study design features and capture the longitudinal and panoramic aspects of pseudoprogression to test superiority of a combination of RRx-001, a novel tumor-associated macrophage polarizing agent in Phase 2, and an anti-PD-L1 antibody in a myeloma preclinical model, comparing to traditional, mean-based mixed effects modeling approaches that did not show statistical significance. Nonparametric p values for the difference of cumulative incidence rates of time to ≥ 50% tumor growth reduction and its associated restricted mean survival times are computed and found to be statistically significant. Kaplan–Meier description of time-to-volume reduction (≥ 50%) coupled with Cox’s proportional hazards model follows the data longitudinally and therefore permits an analysis of immune infiltration resolution, making it an improved method for analysis of preclinical experiments with immuno-oncology agents.
KeywordsImmuno-oncology Pseudoprogression RRx-001 Tumor flare
No funding to declare.
Compliance with ethical standards
Conflict of interest
EpicentRx Inc funds research of molecule RRx-001.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional review board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the clinical study.
- 3.Lewis R, Bhandari A, McKintosh E, Plowman P, Lansley J, Evanson J, Krishnan A (2016). Differentiating tumour progression from pseudoprogression in patients with glioblastoma using multiparametric MRI imaging: data from barts health NHS trust London. Eur J Surg Oncol 42(11):S248–S249CrossRefGoogle Scholar
- 6.Wang S, Martinez-Lage M, Sakai Y, Chawla S, Kim SG, Alonso-Basanta M, Lustig RA, Brem S, Mohan S, Wolf RL, Desai A, Poptani H (2016) Differentiating tumor progression from pseudoprogression in patients with glioblastomas using diffusion tensor imaging and dynamic susceptibility contrast MRI. AJNR Am J Neuroradiol 37(1):28–36CrossRefPubMedGoogle Scholar
- 22.Knox SJ, Ning S, Peehl D, Oronsky B, Scicinski J (2015) Abstract C181: RRx-001 combined with anti-PD-L1 antibody increases the complete response rate in a preclinical myeloma model. Mol Cancer Ther 14(12 Supplement 2):C181. https://doi.org/10.1158/1535-7163.TARG-15-C181